1. Home
  2. SOR vs EIKN Comparison

SOR vs EIKN Comparison

Compare SOR & EIKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Source Capital Inc.

SOR

Source Capital Inc.

N/A

Current Price

$45.30

Market Cap

383.4M

Sector

Finance

ML Signal

N/A

Logo Eikon Therapeutics Inc. Common Stock

EIKN

Eikon Therapeutics Inc. Common Stock

N/A

Current Price

$4.76

Market Cap

316.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOR
EIKN
Founded
N/A
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
383.4M
316.3M
IPO Year
1995
2026

Fundamental Metrics

Financial Performance
Metric
SOR
EIKN
Price
$45.30
$4.76
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $24.00
AVG Volume (30 Days)
6.8K
★ 511.7K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.20
$4.72
52 Week High
$50.41
$16.50

Technical Indicators

Market Signals
Indicator
SOR
EIKN
Relative Strength Index (RSI) 37.13 33.10
Support Level $44.89 N/A
Resistance Level $47.25 $6.82
Average True Range (ATR) 0.92 0.63
MACD -0.22 -0.04
Stochastic Oscillator 0.00 3.10

Price Performance

Historical Comparison
SOR
EIKN

About SOR Source Capital Inc.

Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.

About EIKN Eikon Therapeutics Inc. Common Stock

Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

Share on Social Networks: